EXEL
Price:
$51.91
Market Cap:
$13.05B
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK...[Read more]
Industry
Biotechnology
IPO Date
2000-04-17
Stock Exchange
NASDAQ
Ticker
EXEL
According to Exelixis, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 17.19. This represents a change of 21.91% compared to the average of 14.10 of the last 4 quarters.
The mean historical PE Ratio of Exelixis, Inc. over the last ten years is 21.02. The current 17.19 PE Ratio has changed 8.08% with respect to the historical average. Over the past ten years (40 quarters), EXEL's PE Ratio was at its highest in in the September 2023 quarter at 1.66K. The PE Ratio was at its lowest in in the September 2016 quarter at -72.67.
Average
21.02
Median
21.96
Minimum
-53.25
Maximum
58.46
Discovering the peaks and valleys of Exelixis, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 664.76%
Maximum Annual PE Ratio = 58.46
Minimum Annual Increase = -209.79%
Minimum Annual PE Ratio = -53.25
| Year | PE Ratio | Change |
|---|---|---|
| 2026 | 15.13 | -19.82% |
| 2025 | 18.87 | -48.87% |
| 2023 | 36.91 | 31.16% |
| 2022 | 28.14 | 12.38% |
| 2021 | 25.04 | -55.08% |
| 2020 | 55.75 | 235.39% |
| 2019 | 16.62 | 96.06% |
| 2018 | 8.48 | -85.50% |
| 2017 | 58.46 | -209.79% |
| 2016 | -53.25 | 664.76% |
The current PE Ratio of Exelixis, Inc. (EXEL) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
23.64
5-year avg
24.82
10-year avg
21.02
Exelixis, Inc.’s PE Ratio is less than BioMarin Pharmaceutical Inc. (39.06), greater than Moderna, Inc. (-7.85), greater than Revolution Medicines, Inc. (-22.92), less than Bio-Techne Corporation (81.61), less than Halozyme Therapeutics, Inc. (23.48), greater than Madrigal Pharmaceuticals, Inc. (-39.51), greater than Atrium Therapeutics, Inc. (-4.74), greater than BridgeBio Pharma, Inc. (-17.67), greater than Caris Life Sciences, Inc. (-11.87), less than Align Technology, Inc. (30.50),
| Company | PE Ratio | Market cap |
|---|---|---|
| 39.06 | $10.57B | |
| -7.85 | $25.38B | |
| -22.92 | $34.65B | |
| 81.61 | $9.07B | |
| 23.48 | $8.13B | |
| -39.51 | $11.66B | |
| -4.74 | $216.56M | |
| -17.67 | $12.98B | |
| -11.87 | $5.22B | |
| 30.50 | $13.04B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Exelixis, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Exelixis, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Exelixis, Inc.'s PE Ratio?
How is the PE Ratio calculated for Exelixis, Inc. (EXEL)?
What is the highest PE Ratio for Exelixis, Inc. (EXEL)?
What is the 3-year average PE Ratio for Exelixis, Inc. (EXEL)?
What is the 5-year average PE Ratio for Exelixis, Inc. (EXEL)?
How does the current PE Ratio for Exelixis, Inc. (EXEL) compare to its historical average?